TMO - Thermo Fisher Scientific Inc
The world leader in scientific instrumentation and life science services, supplying laboratories and pharmaceutical manufacturers with the tools to accelerate research.
Finlify Score
48.6 / 100
Data Quality
FULL
Penalty
0.0
Sector
Health Care
Close Price
$576.77
+0.05%
52W Range
$435.27 - $643.99
Market Cap
$186.3B
+0.1%Compared to previous day
2026 Q1 Revenue
$11.0B
-9.9%Changes from last reporting quarter
2026 Q1 EPS
$4.43
Diluted shares
Analyst Rating
36 analysts in latest ratings feed
RSI
71.7
>70 overbought
2Y Range Position
74%
-10.4% from high / +49.6% from low
Beta
0.84
Relative to market benchmark
MACD
3.17
MACD line 20.42 / signal line 17.25
Fundamental Trend
Growth 30.1Financial Health
Quality 57.9Data Quality
FULLValuation Reference
Price Chart
Close price, two-year source window
Finlify Score
HOLD48.6 / 100
Score History
Finlify Score and component trend
Financial Statements
Calendar year view. Figures are estimates only. For official figures, refer to the company website.
| 2026 Q1 | 2025 Q4 | 2025 Q3 | 2025 Q2 | |
|---|---|---|---|---|
| Revenue | $11.0B-9.9% | $12.2B+9.8% | $11.1B+2.5% | $10.9B+4.7% |
| Gross Profit | - | - | - | - |
| Operating Income | $1.9B-17.4% | $2.3B+16.2% | $1.9B+5.7% | $1.8B+6.9% |
| Net Income | $1.7B-15.9% | $2.0B+21.5% | $1.6B+0.2% | $1.6B+6.8% |
Columns use the calendar quarter of each reported period end date. QoQ is shown for adjacent company reporting quarters only.
AI Signal
Generated Jul 25, 2026
The Finlify signal for TMO is HOLD, with a Finlify Score of 48.3 out of 100. This suggests a neutral stance, supported by full data quality and no data quality deductions.
Technical
The Relative Strength score of 47.4/100 appears to be below average, suggesting the asset may not be significantly outperforming its peers over recent periods. However, the Accumulation / Volume score of 67.9/100 indicates some positive buying interest. The RSI(14) at 73.2 suggests the asset may be entering overbought territory following a strong 20-day return of 16.3% and a 60-day return of 22.3%.
Fundamentals
The Fundamental Trend score of 30.1/100 appears relatively low, which may suggest some concerns regarding recent fundamental performance or outlook. The Financial Quality score of 57.9/100 indicates an average financial health. Valuation metrics show a P/E ratio of 30.9x, a P/B of 4.1x, and a P/S of 4.7x, which may suggest a premium valuation. The asset exhibits a Beta of 0.8, indicating it may be less volatile than the broader market, and offers a modest dividend yield of 0.33%.
Macro Context
The macro environment shows elevated inflation metrics with CPI YoY at 3.7% and Core PCE YoY at 3.4%, alongside a 10Y Treasury Yield of 4.7%. This environment, coupled with an unemployment rate of 4.2%, could influence growth-oriented sectors like Life Sciences Tools & Services, potentially impacting future earnings or valuation multiples for TMO.
Key Risks
- Overbought Technicals: The RSI(14) of 73.2, combined with significant recent returns (16.3% over 20 days, 22.3% over 60 days), suggests the asset may be technically overextended.
- Fundamental Trend Concerns: A low Fundamental Trend score of 30.1/100 indicates potential underlying weaknesses or decelerating growth in fundamental performance.
- Premium Valuation: Valuation multiples such as a P/E of 30.9x, P/B of 4.1x, and P/S of 4.7x may suggest the asset is trading at a premium compared to historical averages or peers, potentially limiting upside.